Organogenesis (NASDAQ:ORGO – Get Free Report) issued its earnings results on Tuesday. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11, Zacks reports. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The business had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. During the same period in the prior year, the business earned $0.02 earnings per share. Organogenesis updated its FY 2024 guidance to EPS.
Organogenesis Trading Down 3.7 %
ORGO traded down $0.15 on Friday, hitting $3.86. The company had a trading volume of 226,567 shares, compared to its average volume of 823,099. Organogenesis has a 1 year low of $2.16 and a 1 year high of $4.70. The firm has a market cap of $511.76 million, a P/E ratio of -63.50 and a beta of 1.60. The company’s fifty day moving average price is $2.97 and its 200 day moving average price is $2.81. The company has a current ratio of 3.09, a quick ratio of 2.42 and a debt-to-equity ratio of 0.21.
Organogenesis Company Profile
Further Reading
- Five stocks we like better than Organogenesis
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Top-Performing Non-Leveraged ETFs This Year
- What is the S&P/TSX Index?
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Stock Dividend Cuts Happen Are You Ready?
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.